Center-Authored Papers

Filters: Author is Cassaday, Ryan D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Cassaday RD, Storer BE, Sorror ML, Sandmaier BM, Guthrie KA, Maloney DG, Rajendran JG, Pagel JM, Flowers ME, Green DJ et al..  2015.  Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(2):281-7. Abstract
Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI et al..  2015.  High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.. British journal of haematology. 171(5):788-97. Abstract
Cassaday RD, Goy A, Advani S, Chawla P, Nachankar R, Gandhi M, Gopal AK.  2015.  A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma.. Clinical lymphoma, myeloma & leukemia. Abstract
Cassaday RD, Gopal AK.  2012.  Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.. Best practice & research. Clinical haematology. 25(2):165-74. Abstract
Cassaday RD, Alan Potts D, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC et al..  2016.  Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.. Leukemia & lymphoma. :1-10. Abstract
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC et al..  2013.  Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6. Abstract
Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD et al..  2015.  Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
F
Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD.  2017.  Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.. Clinical lymphoma, myeloma & leukemia. Abstract
G
Gopal AK, Gooley TA, Rajendran JG, Pagel JM, Fisher DR, Maloney DG, Appelbaum FR, Cassaday RD, Shields A, Press OW.  2014.  Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Aged ≥ 60 Years with B-Cell Lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(6):770-5. Abstract
H
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS et al..  2019.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.. Blood. 133(15):1652-1663. Abstract
K
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M et al..  2017.  Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.. The Lancet. Haematology. Abstract
L
Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros JL, Cassaday RD, Reddy NM, Bast MA et al..  2016.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.. British journal of haematology. 175(4):631-640. Abstract
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros JL et al..  2017.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2017722157. Abstract
M
Matesan M, Rajendran J, Press OW, Maloney DG, Storb RF, Cassaday RD, Pagel JM, Oliveira G, Gopal AK.  2014.  90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.. Nuclear medicine communications. 35(11):1132-42. Abstract
O
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM et al..  2015.  Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.. Hematological oncology. 33(4):187-191. Abstract
P
Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI et al..  2015.  Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.. Leukemia & lymphoma. 56(1):92-6. Abstract
Potts AD, Fromm JR, Gopal AK, Cassaday RD.  2017.  Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review.. Case reports in hematology. 2017:2676254. Abstract
S
Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA et al..  2017.  Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.. Leukemia & lymphoma. :1-9. Abstract
U
Ulrickson ML, Puri A, Lindstrom S, Cassaday RD, De Padova N, Becker PS.  2017.  Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm.. American journal of hematology.